### Seattle Sperm Bank



Client/Sending Facility: Seattle Sperm Bank

4915 25th Ave Ne Ste 204 SEATTLE, WA 98105 Ph: (206)588-1484

Account Number:

Client Reference:

Fax: (206) 466-4696 WAB-55

Ordering Physician: JOLLIFFE

Specimen Type: BLOOD

Date Collected: 04/03/2018

Date Received: 04/04/2018

Date Reported: 04/20/2018

LCLS Specimen Number: 093-129-1760-0

Patient Name: 12315. DONOR

Date of Birth:

Gender: M

Patient ID:

Lab Number: (J18-1354 L

Indications: DONOR

Test: Chromosome, Blood, Routine

Cells Counted: 30 Cells Analyzed: 20 Cells Karyotyped: 2 Band Resolution: 500

CYTOGENETIC RESULT: 46,XY

INTERPRETATION: NORMAL MALE KARYOTYPE

Cytogenetic analysis of PHA stimulated cultures has revealed a MALE karyotype with an apparently normal GTG banding pattern in all cells observed.

This result does not exclude the possibility of subtle rearrangements below the resolution of cytogenetics or congenital anomalies due to other etiologies.

Chromosome analysis performed by LabCorp, CLIA 45D0674994. 7207 North Gessner Rd., Houston, TX 77040. Laboratory Director, Venkateswara R Potluri PhD.

TO:

### Seattle Sperm Bank



Client/Sending Facility: Seattle Sperm Bank

4915 25th Ave Ne Ste 204 SEATTLE, WA 98105 Ph: (206)588-1484

Fax: (206) 466-4696 WAB-55

LCLS Specimen Number: 093-129-1760-0

Patient Name: 12315, DONOR

Date of Birth:

Gender: M

Patient ID:

Lab Number: (J18-1354 L

Account Number:

Ordering Physician: J OLLIFFE
Specimen Type: BLOOD

Client Reference:

Date Collected: 04/03/2018 Date Received: 04/04/2018



### Seattle Sperm Bank



Client/Sending Facility: Seattle Sperm Bank

4915 25th Ave Ne Ste 204 SEATTLE, WA 98105 Ph: (206)588-1484

Fax: (206) 466-4696 WAB-55

LCLS Specimen Number: 093-129-1760-0

Patient Name: 12315, DONOR

Date of Birth:

Gender: M

Patient ID:

Lab Number: (J18-1354 L

Account Number:

Ordering Physician: JOLLIFFE

Specimen Type: BLOOD

Client Reference:

Date Collected: 04/03/2018 Date Received: 04/04/2018

0

Hiba Risheg, PhD., FACMG

Patricia Kandalaft, MD Medical Director Stuart Schwartz, PhD

Technical component performed by Laboratory Corporation of America Holdings, 550 17th Ave. Suite 200, SEATTLE, WA, 98122-5789 (800) 676-8033

National Director of Cytogenetics

Professional Component performed by LabCorp/Dynacare CLIA 50D0632667, 550 17th Ave. Suite 200, Seattle WA 98122-5789. Medical Director, Patricia Kandalaft, MD Integrated Genetics is a brand used by Esoterix Genetic Laboratories, LLC, a wholly-owned subsidiary of Laboratory Corporation of America Holdings.

This document contains private and confidential health information protected by state and federal law.



RESULTS RECIPIENT
SEATTLE SPERM BANK

Attn: Dr. Jeffrey Olliffe 4915 25th Ave NE, Suite 204W

Seattle, WA 98105 Phone: (206) 588-1484 Fax: (206) 466-4696 NPI: 1306838271 Report Date: 04/10/2018 MALE

DONOR 12315 DOB:

Ethnicity: Mixed or Other

Caucasian

Sample Type: EDTA Blood Date of Collection: 04/03/2018 Date Received: 04/04/2018 Date Tested: 04/10/2018 Barcode: 11004212276685 Accession ID: CSL3DL2F4E2FZ23 Indication: Egg or sperm donor FEMALE N/A

POSITIVE: CARRIER

# Foresight™ Carrier Screen

#### ABOUT THIS TEST

The **Counsyl Foresight Carrier Screen** utilizes sequencing, maximizing coverage across all DNA regions tested, to help you learn about your chance to have a child with a genetic disease.

#### RESULTS SUMMARY

Risk Details	DONOR 12315	Partner
Panel Information	Foresight Carrier Screen Universal Panel (175 conditions tested)	N/A
POSITIVE: CARRIER Galactosemia	☐ CARRIER* NM_000155.3(GALT):c.1030C>A	The reproductive risk presented is based on a hypothetical pairing with a partner of the same ethnic group. Carrier testing should be considered. See "Next Steps".
Reproductive Risk: 1 in 350 Inheritance: Autosomal Recessive	(Q344K) heterozygote †	

<sup>†</sup>Likely to have a negative impact on gene function. \*Carriers generally do not experience symptoms.

No disease-causing mutations were detected in any other gene tested. A complete list of all conditions tested can be found on page 6.

#### **CLINICAL NOTES**

None

#### **NEXT STEPS**

- Carrier testing should be considered for the diseases specified above for the patient's partner, as both parents must be carriers before a child is at high risk of developing the disease.
- Genetic counseling is recommended and patients may wish to discuss any positive results with blood relatives, as there is an increased chance that they are also carriers.



SEATTLE SPERM BANK Attn: Dr. Jeffrey Olliffe

NPI: 1306838271

Report Date: 04/10/2018

MALE **DONOR 12315** 

DOB: Ethnicity: Mixed or Other

Caucasian

Barcode: 11004212276685

FEMALE N/A

POSITIVE: CARRIER Galactosemia

Gene: GALT | Inheritance Pattern: Autosomal Recessive

Reproductive risk: 1 in 350 Risk before testing: 1 in 30,000

Patient	DONOR 12315	No partner tested
Result	<b>□</b> Carrier	N/A
Variant(s)	NM_000155.3(GALT):c.1030C>A(Q344K) heterozygote <sup>†</sup>	N/A
Methodology	Sequencing with copy number analysis	N/A
Interpretation	This individual is a carrier of galactosemia. Carriers generally do not experience symptoms.	N/A
Detection rate	>99%	N/A
Exons tested	NM_000155:1-11.	N/A

<sup>†</sup>Likely to have a negative impact on gene function.

### What is Galactosemia?

Galactosemia is a treatable inherited disease that reduces the body's ability to metabolize galactose, a simple sugar found in milk. The classic form of galactosemia can be fatal without prompt treatment and careful management. Because milk is a staple of an infant's diet, diagnosis and treatment within the first week of life is critical to avoiding mental retardation and life-threatening complications.

Classic galactosemia, the most severe form of the disease, is caused by a deficiency in an enzyme called galactose-1-phosphate uridyltransferase. People with classic galactosemia have less than 5% of the normal activity in this enzyme. After only a few days of drinking milk, including breast milk, an infant with classic galactosemia will show symptoms including loss of appetite, jaundice, vomiting, lethargy, and convulsions. Without immediate and vigilant lifelong treatment, children with the condition will experience life-threatening complications such as severe infections, cirrhosis of the liver, and mental retardation. Even with treatment, children can still develop cataracts, speech problems, stunted growth and motor function, and learning disabilities, and most females will eventually develop menstrual irregularities and go through premature menopause.

Duarte galactosemia is a much milder form of the disease in which a person has 25 to 50% of the normal amount of galactose-1-phosphate uridyltransferase. People with Duarte galactosemia generally do not suffer any of the symptoms of classic galactosemia.

Please note that galactosemia is not the same as lactose intolerance, a more common and less serious condition.

### How common is Galactosemia?

Classic galactosemia affects approximately 1 in 30,000 newborns. It is thought that 6% of the U.S. population (6 in 100) is a carrier of Duarte galactosemia.



RESULTS RECIPIENT SEATTLE SPERM BANK Attn: Dr. Jeffrey Olliffe

NPI: 1306838271

Report Date: 04/10/2018

MALE DONOR 12315 DOB: Ethnicity: Mixed or Other

Caucasian Barcode: 11004212276685 FEMALE N/A

### How is Galactosemia treated?

People with classic galactosemia must monitor their galactose-1-phosphate levels with regular blood tests follow a lifelong diet free of milk, milk products, or other foods containing lactose. Infants should be fed with galactose-free formulas such as soy formula or Nutramigen, a hypoallergenic formula with no galactose, lactose, or soy. As children learn to feed themselves, parents must teach them how to read product labels so they can avoid any food containing milk, dry milk, milk products, and other galactose-containing foods. Often they require calcium supplements to avoid calcium deficiency.

There is debate on whether people with Duarte galactosemia need to adhere to a galactose-free diet. Some medical professionals recommend modifying an affected person's diet while others do not. The decision whether or not to treat a person with Duarte galactosemia may depend upon his or her level of enzyme activity.

People with galactosemia should work with a nutritionist to determine the best course of treatment.

# What is the prognosis for a person with Galactosemia?

Most people who are diagnosed early with classic galactosemia and carefully follow a galactose-free diet can have a normal lifespan. They are still at risk, however, for cataracts, speech defects, poor growth, poor intellectual function, neurologic deficits and ovarian failure (in women). If the treatment of classic galactosemia is not prompt and consistent, life-threatening complications and irreversible mental retardation can result.

Duarte galactosemia has not been associated with any long-term health problems.



SEATTLE SPERM BANK Attn: Dr. Jeffrey Olliffe NPI: 1306838271

Report Date: 04/10/2018

MALE **DONOR 12315** DOB:

Ethnicity: Mixed or Other

Caucasian

Barcode: 11004212276685

FEMALE N/A

# Methods and Limitations

DONOR 12315 [Foresight Carrier Screen]: sequencing with copy number analysis, spinal muscular atrophy, and analysis of homologous regions.

# Sequencing with copy number analysis

High-throughput sequencing and read depth-based copy number analysis are used to analyze the listed exons, as well as selected intergenic and intronic regions, of the genes in the Conditions Tested section of the report. The region of interest (ROI) of the test comprises these regions, in addition to the 20 intronic bases flanking each exon. In a minority of cases where genomic features (e.g., long homopolymers) compromise calling fidelity, the affected intronic bases are not included in the ROI. The ROI is sequenced to high coverage and the sequences are compared to standards and references of normal variation. More than 99% of all bases in the ROI are sequenced at greater than the minimum read depth. Mutations may not be detected in areas of lower sequence coverage. Small insertions and deletions may not be as accurately determined as single nucleotide variants. Genes that have closely related pseudogenes may be addressed by a different method. CFTR and DMD testing includes analysis for both large (exon-level) deletions and duplications with an average sensitivity of 99%, while other genes are only analyzed for large deletions with a sensitivity of >75%. However, the sensitivity may be higher for selected founder deletions. If GJB2 is tested, two large upstream deletions which overlap G/B6 and affect the expression of G/B2, del(G/B6-D13S1830) and del(G/B6-D13S1854), are also analyzed. Mosaicism or somatic variants present at low levels may not be detected. If detected, these may not be reported.

Detection rates are determined by using literature to estimate the fraction of disease alleles, weighted by frequency, that the methodology is unable to detect. Detection rates only account for analytical sensitivity and certain variants that have been previously described in the literature may not be reported if there is insufficient evidence for pathogenicity. Detection rates do not account for the disease-specific rates of de novo mutations.

All variants that are a recognized cause of the disease will be reported. In addition, variants that have not previously been established as a recognized cause of disease may be identified. In these cases, only variants classified as "likely" pathogenic are reported. Likely pathogenic variants are described elsewhere in the report as "likely to have a negative impact on gene function". Likely pathogenic variants are evaluated and classified by assessing the nature of the variant and reviewing reports of allele frequencies in cases and controls, functional studies, variant annotation and effect prediction, and segregation studies. Exon level duplications are assumed to be in tandem and are classified according to their predicted effect on the reading frame. Benign variants, variants of uncertain significance, and variants not directly associated with the intended disease phenotype are not reported. Curation summaries of reported variants are available upon request.

### Spinal muscular atrophy

Targeted copy number analysis is used to determine the copy number of exon 7 of the SMN1 gene relative to other genes. Other mutations may interfere with this analysis. Some individuals with two copies of SMN1 are carriers with two SMN1 genes on one chromosome and a SMN1 deletion on the other chromosome. This is more likely in individuals who have 2 copies of the SMN1 gene and are positive for the g.27134T>G SNP, which affects the reported residual risk; Ashkenazi Jewish or Asian patients with this genotype have a high post-test likelihood of being carriers for SMA and are reported as carriers. The g.27134T>G SNP is only reported in individuals who have 2 copies of SMN1.

## Analysis of homologous regions

A combination of high-throughput sequencing, read depth-based copy number analysis, and targeted genotyping is used to determine the number of functional gene copies and/or the presence of selected loss of function mutations in certain genes that have homology to other regions. The precise breakpoints of large deletions in these genes cannot be determined, but are estimated from copy number analysis. High numbers of pseudogene copies may interfere with this analysis.

If CYP21A2 is tested, patients who have one or more additional copies of the CYP21A2 gene and a loss of function mutation may not actually be a carrier of 21-hydroxylase-deficient congenital adrenal hyperplasia (CAH). Because the true incidence of non-classic CAH is unknown, the residual carrier and reproductive risk numbers on the report are only based on published incidences for classic CAH. However, the published prevalence of non-classic CAH is highest in individuals of Ashkenazi Jewish, Hispanic, Italian, and Yugoslav descent. Therefore, the residual and reproductive risks are likely an underestimate of overall chances for 21-hydroxylase-deficient CAH, especially in the aforementioned populations, as they do not account for non-classic CAH. If HBA1/HBA2 are tested, some individuals with four alpha globin genes may be carriers, with three genes on one chromosome and a deletion on the other chromosome. This and similar, but rare, carrier states, where complementary changes exist in both the gene and a pseudogene, may not be detected by the assay.



l

RESULTS RECIPIENT

SEATTLE SPERM BANK Attn: Dr. Jeffrey Olliffe NPI: 1306838271

Report Date: 04/10/2018

MALE DONOR 12315

DOB: Ethnicity: Mixed or Other

Caucasian

Barcode: 11004212276685

FEMALE N/A

### Limitations

In an unknown number of cases, nearby genetic variants may interfere with mutation detection. Other possible sources of diagnostic error include sample mix-up, trace contamination, bone marrow transplantation, blood transfusions and technical errors. This test is designed to detect and report germline alterations. While somatic variants present at low levels may be detected, these may not be reported. If more than one variant is detected in a gene, additional studies may be necessary to determine if those variants lie on the same chromosome or different chromosomes. The test does not fully address all inherited forms of intellectual disability, birth defects and genetic disease. A family history of any of these conditions may warrant additional evaluation. Furthermore, not all mutations will be identified in the genes analyzed and additional testing may be beneficial for some patients. For example, individuals of African, Southeast Asian, and Mediterranean ancestry are at increased risk for being carriers for hemoglobinopathies, which can be identified by CBC and hemoglobin electrophoresis or HPLC (ACOG Practice Bulletin No. 78. Obstet. Gynecol. 2007;109:229-37).

This test was developed and its performance characteristics determined by Counsyl, Inc. It has not been cleared or approved by the US Food and Drug Administration (FDA). The FDA does not require this test to go through premarket review. This test is used for clinical purposes. It should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. These results are adjunctive to the ordering physician's evaluation. CLIA Number: #05D1102604.

LABORATORY DIRECTOR

Hyunseok Kang

H. Peter Kang, MD, MS, FCAP

Report content approved by Bethany Buckley, PhD, FACMG on Apr 11, 2018



SEATTLE SPERM BANK

Attn: Dr. Jeffrey Olliffe NPI: 1306838271 Report Date: 04/10/2018 **DONOR 12315** 

MALE

DOB: Ethnicity: Mixed or Other

Caucasian

Barcode: 11004212276685

FEMALE N/A

# Conditions Tested

11-beta-hydroxylase-deficient Congenital Adrenal Hyperplasia - Gene: CYP11B1. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000497:1-9. Detection Rate: Mixed or Other Caucasian 94%.

21-hydroxylase-deficient Congenital Adrenal Hyperplasia - Gene: CYP21A2. Autosomal Recessive. Analysis of Homologous Regions. Variants (13): CYP21A2 deletion, CYP21A2 duplication, CYP21A2 triplication, G111Vfs\*21, I173N, L308Ffs\*6, P31L, Q319\*, Q319\*+CYP21A2dup, R357W, V281L, [I237N;V238E;M240K], c.293-13C>G. Detection Rate: Mixed or Other Caucasian 96%.

6-pyruvoyl-tetrahydropterin Synthase Deficiency - Gene: PTS. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000317:1-6. Detection Rate: Mixed or Other Caucasian >99%.

ABCC8-related Hyperinsulinism - Gene: ABCC8. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000352:1-39. Detection Rate: Mixed or Other Caucasian >99%.

Adenosine Deaminase Deficiency - Gene: ADA. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000022:1-12. Detection Rate: Mixed or Other Caucasian >99%.

Alpha Thalassemia - Genes: HBA1, HBA2. Autosomal Recessive. Analysis of Homologous Regions. Variants (13): -(alpha)20.5, --BRIT, --MEDI, --MEDII, --SEA, -- THAI or --FIL, -alpha3.7, -alpha4.2, HBA1+HBA2 deletion, Hb Constant Spring, anti3.7, anti4.2, del HS-40. Detection Rate: Unknown due to rarity of disease.

Alpha-mannosidosis - Gene: MAN2B1. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000528:1-23. Detection Rate: Mixed or Other Caucasian >99%.

Alpha-sarcoglycanopathy - Gene: SGCA. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000023:1-9. Detection Rate: Mixed or Other Caucasian >99%.

Alstrom Syndrome - Gene: ALMS1. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_015120:1-23. Detection Rate: Mixed or Other Caucasian >99%.

AMT-related Glycine Encephalopathy - Gene: AMT. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000481:1-9. Detection Rate: Mixed or Other Caucasian >99%.

Andermann Syndrome - Gene: SLC12A6. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_133647:1-25. Detection Rate: Mixed or Other Caucasian >99%.

Argininemia - Gene: ARG1. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_001244438:1-8. Detection Rate: Mixed or Other Caucasian 97%.

Argininosuccinic Aciduria - Gene: ASL. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_001024943:1-16. Detection Rate: Mixed or Other Caucasian >99%.

ARSACS - Gene: SACS. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_014363:2-10. Detection Rate: Mixed or Other Caucasian 99%. Aspartylglycosaminuria - Gene: AGA. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000027:1-9. Detection Rate: Mixed or Other Caucasian >99%.

Ataxia with Vitamin E Deficiency - Gene: TTPA. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000370:1-5. Detection Rate: Mixed or Other Caucasian >99%.

Ataxia-telangiectasia - Gene: ATM. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000051:2-63. Detection Rate: Mixed or Other Caucasian 98%.

ATP7A-related Disorders - Gene: ATP7A. X-linked Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000052:2-23. Detection Rate: Mixed or Other

**Autosomal Recessive Osteopetrosis Type 1** - Gene: TCIRG1. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_006019:2-20. Detection Rate: Mixed or Other Caucasian >99%.

**Bardet-Biedl Syndrome**, **BBS1-related** - Gene: BBS1. Autosomal Recessive. Sequencing with Copy Number Analysis. **Exons**: NM\_024649:1-17. **Detection Rate**: Mixed or Other Caucasian >99%.

Bardet-Biedl Syndrome, BBS10-related - Gene: BBS10. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_024685:1-2. Detection Rate: Mixed or Other Caucasian >99%.

Bardet-Biedl Syndrome, BBS12-related - Gene: BBS12. Autosomal Recessive. Sequencing with Copy Number Analysis. Exon: NM\_152618:2. Detection Rate: Mixed or Other Caucasian >99%.

Bardet-Biedl Syndrome, BBS2-related - Gene: BBS2. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_031885:1-17. Detection Rate: Mixed or Other Caucasian >99%.

**Beta-sarcoglycanopathy** - Gene: SGCB. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000232:1-6. **Detection** Rate: Mixed or Other Caucasian >99%.

**Biotinidase Deficiency** - Gene: BTD. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000060:1-4. **Detection Rate**: Mixed or Other Caucasian >99%.

**Bloom Syndrome** - Gene: BLM. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000057;2-22. Detection Rate: Mixed or Other Caucasian >99%.

Calpainopathy - Gene: CAPN3. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000070:1-24. Detection Rate: Mixed or Other Caucasian >99%.

Canavan Disease - Gene: ASPA. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000049:1-6. Detection Rate: Mixed or Other Caucasian 98%.

Carbamoylphosphate Synthetase I Deficiency - Gene: CPS1. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_001875:1-38. Detection Rate: Mixed or Other Caucasian >99%.

Carnitine Palmitoyltransferase IA Deficiency - Gene: CPT1A. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_001876:2-19. Detection Rate: Mixed or Other Caucasian >99%.

Carnitine Palmitoyltransferase II Deficiency - Gene: CPT2. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000098:1-5. Detection Rate: Mixed or Other Caucasian >99%.

Cartilage-hair Hypoplasia - Gene: RMRP. Autosomal Recessive. Sequencing with Copy Number Analysis. Exon: NR\_003051:1. Detection Rate: Mixed or Other Caucasian >99%.

Cerebrotendinous Xanthomatosis - Gene: CYP27A1. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000784:1-9. Detection Rate: Mixed or Other Caucasian >99%.

Citrullinemia Type 1 - Gene: ASS1. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000050:3-16. Detection Rate: Mixed or Other Caucasian >99%.

CLN3-related Neuronal Ceroid Lipofuscinosis - Gene: CLN3. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_001042432:2-16. Detection Rate: Mixed or Other Caucasian >99%.

CLN5-related Neuronal Ceroid Lipofuscinosis - Gene: CLN5. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_006493:1-4. Detection Rate: Mixed or Other Caucasian >99%.

CLN6-related Neuronal Ceroid Lipofuscinosis - Gene: CLN6. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_017882:1-7. Detection Rate: Mixed or Other Caucasian >99%.

**Cohen Syndrome** - Gene: VPS13B. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_017890:2-62. Detection Rate: Mixed or Other Caucasian 97%.

COL4A3-related Alport Syndrome - Gene: COL4A3. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000091:1-52. Detection Rate: Mixed or Other Caucasian 97%.

COL4A4-related Alport Syndrome - Gene: COL4A4. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000092:2-48. Detection Rate: Mixed or Other Caucasian 98%.

Congenital Disorder of Glycosylation Type Ia - Gene: PMM2. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000303:1-8. Detection Rate: Mixed or Other Caucasian >99%.

Congenital Disorder of Glycosylation Type Ib - Gene: MPI. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_002435:1-8. Detection Rate: Mixed or Other Caucasian >99%.



SEATTLE SPERM BANK

Attn: Dr. Jeffrey Olliffe NPI: 1306838271

Report Date: 04/10/2018

MALE

**DONOR 12315** 

DOB: Ethnicity: Mixed or Other

Caucasian

Barcode: 11004212276685

FEMALE N/A

Congenital Disorder of Glycosylation Type Ic - Gene: ALG6. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_013339:2-15. Detection Rate: Mixed or Other Caucasian >99%.

Congenital Finnish Nephrosis - Gene: NPHS1. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_004646:1-29. Detection Rate: Mixed or Other Caucasian >99%.

Costeff Optic Atrophy Syndrome - Gene: OPA3. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_025136:1-2, Detection Rate: Mixed or Other Caucasian >99%.

Cystic Fibrosis - Gene: CFTR. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000492:1-27. IVS8-5T allele analysis is only reported in the presence of the R117H mutation. Detection Rate: Mixed or Other Caucasian >99%. Cystinosis - Gene: CTNS. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_004937:3-12. Detection Rate: Mixed or Other Caucasian >99%. D-bifunctional Protein Deficiency - Gene: HSD17B4. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000414:1-24. Detection Rate: Mixed or Other Caucasian 98%.

**Delta-sarcoglycanopathy** - **Gene:** SGCD. Autosomal Recessive. Sequencing with Copy Number Analysis. **Exons:** NM\_000337:2-9. **Detection Rate:** Mixed or Other Caucasian 99%.

**Dysferlinopathy** - **Gene**: DYSF. Autosomal Recessive. Sequencing with Copy Number Analysis. **Exons**: NM\_001130987:1-56. **Detection Rate**: Mixed or Other Caucasian 98%

Dystrophinopathy (Including Duchenne/Becker Muscular Dystrophy) - Gene: DMD. X-linked Recessive. Sequencing with Copy Number Analysis. Exons: NM\_004006:1-79. Detection Rate: Mixed or Other Caucasian >99%.

**ERCC6-related Disorders** - **Gene**: ERCC6. Autosomal Recessive. Sequencing with Copy Number Analysis. **Exons**: NM\_000124:2-21. **Detection Rate**: Mixed or Other Caucasian 99%.

**ERCC8-related Disorders - Gene:** ERCC8. Autosomal Recessive. Sequencing with Copy Number Analysis. **Exons:** NM\_000082:1-12. **Detection Rate:** Mixed or Other Caucasian 95%.

**EVC-related Ellis-van Creveld Syndrome** - Gene: EVC. Autosomal Recessive. Sequencing with Copy Number Analysis. **Exons:** NM\_153717:1-21. **Detection Rate:** Mixed or Other Caucasian 96%.

**EVC2-related Ellis-van Creveld Syndrome** - Gene: EVC2. Autosomal Recessive. Sequencing with Copy Number Analysis. **Exons:** NM\_147127:1-22. **Detection Rate:** Mixed or Other Caucasian >99%.

Fabry Disease - Gene: GLA. X-linked Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000169:1-7. Detection Rate: Mixed or Other Caucasian 98%. Familial Dysautonomia - Gene: IKBKAP. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_003640:2-37. Detection Rate: Mixed or Other Caucasian >99%.

Familial Mediterranean Fever - Gene: MEFV. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000243:1-10. Detection Rate: Mixed or Other Caucasian >99%.

Fanconi Anemia Complementation Group A - Gene: FANCA. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000135:1-43. Detection Rate: Mixed or Other Caucasian 92%.

Fanconi Anemia Type C - Gene: FANCC. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000136:2-15. Detection Rate: Mixed or Other Caucasian >99%.

**FKRP-related Disorders** - **Gene**: FKRP. Autosomal Recessive. Sequencing with Copy Number Analysis. **Exon**: NM\_024301:4. **Detection Rate**: Mixed or Other Caucasian >99%.

**FKTN-related Disorders - Gene**: FKTN. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_001079802:3-11. Detection Rate: Mixed or Other Caucasian >99%.

Galactokinase Deficiency - Gene: GALK1. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000154:1-8. Detection Rate: Mixed or Other Caucasian >99%

Galactosemia - Gene: GALT. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000155:1-11. Detection Rate: Mixed or Other Caucasian >99%. Gamma-sarcoglycanopathy - Gene: SGCG. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000231:2-8. Detection Rate: Mixed or Other Caucasian 88%.

**Gaucher Disease** - Gene: GBA. Autosomal Recessive. Analysis of Homologous Regions. **Variants** (10): D409V, D448H, IVS2+1G>A, L444P, N3705, R463C, R463H, R496H, V394L, p.L29Afs\*18. **Detection Rate**: Mixed or Other Caucasian 60%.

GJB2-related DFNB1 Nonsyndromic Hearing Loss and Deafness - Gene: GJB2.

Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_004004:1-2. Detection Rate: Mixed or Other Caucasian >99%.

**GLB1-related Disorders** - Gene: GLB1. Autosomal Recessive. Sequencing with Copy Number Analysis. **Exons**: NM\_000404:1-16. Detection Rate: Mixed or Other Caucasian >99%.

**GLDC-related Glycine Encephalopathy** - Gene: GLDC. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000170:1-25. Detection Rate: Mixed or Other Caucasian 94%.

**Glutaric Acidemia Type 1** - Gene: GCDH. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000159:2-12. **Detection Rate**: Mixed or Other Caucasian >99%.

**Glycogen Storage Disease Type Ia** - Gene: G6PC. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000151:1-5. Detection Rate: Mixed or Other Caucasian >99%.

**Glycogen Storage Disease Type Ib** - Gene: SLC37A4. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_001164277:3-11. Detection Rate: Mixed or Other Caucasian >99%.

**Glycogen Storage Disease Type III** - Gene: AGL. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000642:2-34, Detection Rate: Mixed or Other Caucasian >99%.

**GNPTAB-related Disorders** - Gene: GNPTAB. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_024312:1-21. Detection Rate: Mixed or Other Caucasian >99%.

**GRACILE Syndrome** - Gene: BCS1L. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_004328:3-9. Detection Rate: Mixed or Other Caucasian >99%.

**HADHA-related Disorders** - Gene: HADHA. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000182:1-20. Detection Rate: Mixed or Other Caucasian >99%.

Hb Beta Chain-related Hemoglobinopathy (Including Beta Thalassemia and Sickle Cell Disease) - Gene: HBB. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000518:1-3. Detection Rate: Mixed or Other Caucasian >99%.

Hereditary Fructose Intolerance - Gene: ALDOB. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000035:2-9. Detection Rate: Mixed or Other Caucasian >99%.

Herlitz Junctional Epidermolysis Bullosa, LAMA3-related - Gene: LAMA3. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000227:1-38. Detection Rate: Mixed or Other Caucasian >99%.

Herlitz Junctional Epidermolysis Bullosa, LAMB3-related - Gene: LAMB3. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000228:2-23. Detection Rate: Mixed or Other Caucasian >99%.

Herlitz Junctional Epidermolysis Bullosa, LAMC2-related - Gene: LAMC2. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_005562:1-23. Detection Rate: Mixed or Other Caucasian >99%.

Hexosaminidase A Deficiency (Including Tay-Sachs Disease) - Gene: HEXA. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000520:1-14. Detection Rate: Mixed or Other Caucasian >99%.

**HMG-CoA Lyase Deficiency** - Gene: HMGCL. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000191:1-9. Detection Rate: Mixed or Other Caucasian 98%.

Holocarboxylase Synthetase Deficiency - Gene: HLCS. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons; NM\_000411:4-12. Detection Rate: Mixed or Other Caucasian >99%.

Homocystinuria Caused by Cystathionine Beta-synthase Deficiency - Gene: CBS. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000071:3-17. Detection Rate: Mixed or Other Caucasian >99%.

**Hydrolethalus Syndrome** - Gene: HYLS1. Autosomal Recessive. Sequencing with Copy Number Analysis. Exon: NM\_001134793:3. Detection Rate: Mixed or Other Caucasian >99%.

**Hypophosphatasia, Autosomal Recessive - Gene**: ALPL. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000478:2-12. Detection Rate: Mixed or Other Caucasian >99%.

Inclusion Body Myopathy 2 - Gene: GNE. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_001128227;1-12. Detection Rate: Mixed or Other Caucasian >99%.

**Isovaleric Acidemia** - Gene: IVD. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_002225:1-12. Detection Rate: Mixed or Other Caucasian > 99%.



#### SEATTLE SPERM BANK

Attn: Dr. Jeffrey Olliffe NPI: 1306838271

Report Date: 04/10/2018

MALE DONOR 12315

DOB: Ethnicity: Mixed or Other

Caucasian

Barcode: 11004212276685

FEMALE N/A

**Joubert Syndrome 2** - Gene: TMEM216. Autosomal Recessive. Sequencing with Copy Number Analysis. **Exons**: NM\_001173990:1-5. **Detection Rate**: Mixed or Other Caucasian >99%.

KCNJ11-related Familial Hyperinsulinism - Gene: KCNJ11. Autosomal Recessive. Sequencing with Copy Number Analysis. Exon: NM\_000525:1. Detection Rate: Mixed or Other Caucasian >99%.

Krabbe Disease - Gene: GALC. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000153:1-17. Detection Rate: Mixed or Other Caucasian >99%. LAMA2-related Muscular Dystrophy - Gene: LAMA2. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000426:1-65. Detection Rate: Mixed or Other Caucasian >99%.

**Leigh Syndrome, French-Canadian Type** - Gene: LRPPRC. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_133259:1-38. Detection Rate: Mixed or Other Caucasian >99%.

**Lipoamide Dehydrogenase Deficiency - Gene**: DLD. Autosomal Recessive. Sequencing with Copy Number Analysis. **Exons:** NM\_000108:1-14. **Detection Rate**: Mixed or Other Caucasian >99%.

**Lipoid Congenital Adrenal Hyperplasia** - Gene: STAR. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000349:1-7. **Detection Rate**: Mixed or Other Caucasian >99%.

**Lysosomal Acid Lipase Deficiency - Gene**: LIPA. Autosomal Recessive. Sequencing with Copy Number Analysis. **Exons**: NM\_000235:2-10. **Detection Rate**: Mixed or Other Caucasian >99%.

Maple Syrup Urine Disease Type 1B - Gene: BCKDHB, Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_183050:1-10. Detection Rate: Mixed or Other Caucasian >99%.

Maple Syrup Urine Disease Type Ia - Gene: BCKDHA. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000709:1-9. Detection Rate: Mixed or Other Caucasian >99%.

Maple Syrup Urine Disease Type II - Gene: DBT. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_001918:1-11. Detection Rate: Mixed or Other Caucasian 96%

Medium Chain Acyl-CoA Dehydrogenase Deficiency - Gene: ACADM. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000016:1-12. Detection Rate: Mixed or Other Caucasian >99%.

Megalencephalic Leukoencephalopathy with Subcortical Cysts - Gene: MLC1. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_015166:2-12. Detection Rate: Mixed or Other Caucasian >99%.

Metachromatic Leukodystrophy - Gene: ARSA. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000487:1-8. Detection Rate: Mixed or Other Caucasian >99%.

Methylmalonic Acidemia, cblA Type - Gene: MMAA. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_172250:2-7. Detection Rate: Mixed or Other Caucasian >99%.

Methylmalonic Acidemia, cblB Type - Gene: MMAB. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_052845:1-9. Detection Rate: Mixed or Other Caucasian >99%.

Methylmalonic Aciduria and Homocystinuria, cblC Type - Gene: MMACHC. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_015506:1-4. Detection Rate: Mixed or Other Caucasian >99%.

MKS1-related Disorders - Gene: MKS1. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_017777:1-18. Detection Rate: Mixed or Other Caucasian >99%.

Mucolipidosis III Gamma - Gene: GNPTG. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_032520:1-11. Detection Rate: Mixed or Other Caucasian >99%.

Mucolipidosis IV - Gene: MCOLN1. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_020533:1-14. Detection Rate: Mixed or Other Caucasian > 99%.

**Mucopolysaccharidosis Type I** - Gene: IDUA. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000203:1-14. Detection Rate: Mixed or Other Caucasian >99%.

Mucopolysaccharidosis Type II - Gene: IDS. X-linked Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000202:1-9. Detection Rate: Mixed or Other Caucasian 88%.

**Mucopolysaccharidosis Type IIIA** - Gene: SGSH. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000199:1-8. Detection Rate: Mixed or Other Caucasian >99%.

Mucopolysaccharidosis Type IIIB - Gene: NAGLU. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000263:1-6. Detection Rate: Mixed or Other Caucasian >99%.

Mucopolysaccharidosis Type IIIC - Gene: HGSNAT. Autosomal Recessive.
Sequencing with Copy Number Analysis. Exons: NM\_152419:1-18. Detection Rate: Mixed or Other Caucasian >99%.

Muscle-eye-brain Disease - Gene: POMGNT1. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_017739:2-22. Detection Rate: Mixed or Other Caucasian 96%.

**MUT-related Methylmalonic Acidemia** - Gene: MUT. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000255:2-13. Detection Rate: Mixed or Other Caucasian >99%.

MYO7A-related Disorders - Gene: MYO7A. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000260:2-49. Detection Rate: Mixed or Other Caucasian >99%.

**NEB-related Nemaline Myopathy** - Gene: NEB. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_001271208:3-80,117-183. Detection Rate: Mixed or Other Caucasian 92%.

**Nephrotic Syndrome, NPHS2-related** - Gene: NPHS2. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_014625:1-8. Detection Rate: Mixed or Other Caucasian >99%.

Niemann-Pick Disease Type C - Gene: NPC1. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000271:1-25. Detection Rate: Mixed or Other Caucasian >99%.

Niemann-Pick Disease Type C2 - Gene: NPC2. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_006432:1-5. Detection Rate: Mixed or Other Caucasian >99%.

Niemann-Pick Disease, SMPD1-associated - Gene: SMPD1. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000543:1-6. Detection Rate: Mixed or Other Caucasian >99%.

Nijmegen Breakage Syndrome - Gene: NBN. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_002485:1-16. Detection Rate: Mixed or Other Caucasian >99%.

Northern Epilepsy - Gene: CLN8. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_018941:2-3. Detection Rate: Mixed or Other Caucasian >99%.

Ornithine Transcarbamylase Deficiency - Gene: OTC. X-linked Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000531:1-10. Detection Rate: Mixed or Other Caucasian 97%.

PCCA-related Propionic Acidemia - Gene: PCCA. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000282:1-24. Detection Rate: Mixed or Other Caucasian 95%.

PCCB-related Propionic Acidemia - Gene: PCCB. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_001178014:1-16. Detection Rate: Mixed or Other Caucasian >99%.

PCDH15-related Disorders - Gene: PCDH15. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_033056:2-33. Detection Rate: Mixed or Other Caucasian 93%.

**Pendred Syndrome** - Gene: SLC26A4. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000441:2-21. Detection Rate: Mixed or Other Caucasian >99%.

**Peroxisome Biogenesis Disorder Type 3 - Gene**: PEX12. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000286:1-3. Detection Rate: Mixed or Other Caucasian >99%.

Peroxisome Biogenesis Disorder Type 4 - Gene: PEX6. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000287:1-17. Detection Rate: Mixed or Other Caucasian 97%.

**Peroxisome Biogenesis Disorder Type 5** - Gene: PEX2. Autosomal Recessive. Sequencing with Copy Number Analysis. Exon: NM\_000318:4. Detection Rate: Mixed or Other Caucasian >99%.

Peroxisome Biogenesis Disorder Type 6 - Gene: PEX10. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_153818:1-6. Detection Rate: Mixed or Other Caucasian >99%.

**PEX1-related Zellweger Syndrome Spectrum** - Gene: PEX1. Autosomal Recessive. Sequencing with Copy Number Analysis. **Exons**: NM\_000466:1-24. **Detection Rate**: Mixed or Other Caucasian >99%.

Phenylalanine Hydroxylase Deficiency - Gene: PAH. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000277:1-13. Detection Rate: Mixed or Other Caucasian >99%.



#### SEATTLE SPERM BANK

Attn: Dr. Jeffrey Olliffe NPI: 1306838271

Report Date: 04/10/2018

MALE

**DONOR 12315** 

DOB:

Caucasian

Barcode: 11004212276685

Ethnicity: Mixed or Other

FEMALE N/A

PKHD1-related Autosomal Recessive Polycystic Kidney Disease - Gene: PKHD1. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_138694:2-67. Detection Rate: Mixed or Other Caucasian >99%.

Polyglandular Autoimmune Syndrome Type 1 - Gene: AIRE. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000383:1-14. Detection Rate: Mixed or Other Caucasian >99%.

Pompe Disease - Gene: GAA. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000152:2-20. Detection Rate: Mixed or Other Caucasian 98%. PPT1-related Neuronal Ceroid Lipofuscinosis - Gene: PPT1. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000310:1-9. Detection Rate: Mixed or Other Caucasian >99%.

**Primary Carnitine Deficiency** - Gene: SLC22A5. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_003060:1-10. Detection Rate: Mixed or Other Caucasian >99%.

**Primary Hyperoxaluria Type 1** - Gene: AGXT. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000030:1-11. Detection Rate: Mixed or Other Caucasian >99%.

Primary Hyperoxaluria Type 2 - Gene: GRHPR. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_012203:1-9. Detection Rate: Mixed or Other Caucasian >99%.

Primary Hyperoxaluria Type 3 - Gene: HOGA1. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_138413:1-7. Detection Rate: Mixed or Other Caucasian >99%.

PROP1-related Combined Pituitary Hormone Deficiency - Gene: PROP1. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_006261:1-3. Detection Rate: Mixed or Other Caucasian >99%.

**Pycnodysostosis** - Gene: CTSK. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000396:2-8. Detection Rate: Mixed or Other Caucasian >99%.

Pyruvate Carboxylase Deficiency - Gene: PC. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_022172:2-21. Detection Rate: Mixed or Other Caucasian >99%.

Rhizomelic Chondrodysplasia Punctata Type 1 - Gene: PEX7. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000288:1-10. Detection Rate: Mixed or Other Caucasian >99%.

RTEL1-related Disorders - Gene: RTEL1. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_032957:2-35. Detection Rate: Mixed or Other Caucasian >99%

Salla Disease - Gene: SLC17A5. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_012434:1-11. Detection Rate: Mixed or Other Caucasian 98%.

Sandhoff Disease - Gene: HEXB. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000521:1-14. Detection Rate: Mixed or Other Caucasian >00%

Segawa Syndrome - Gene: TH. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000360:1-13. Detection Rate: Mixed or Other Caucasian > 99%

Short Chain Acyl-CoA Dehydrogenase Deficiency - Gene: ACADS. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000017:1-10. Detection Rate: Mixed or Other Caucasian >99%.

Sjogren-Larsson Syndrome - Gene: ALDH3A2. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000382:1-10. Detection Rate: Mixed or Other Caucasian 97%.

Smith-Lemli-Opitz Syndrome - Gene: DHCR7. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_001360:3-9. Detection Rate: Mixed or Other Caucasian >99%.

Spastic Paraplegia Type 15 - Gene: ZFYVE26. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_015346:2-42. Detection Rate: Mixed or Other Caucasian >99%.

Spinal Muscular Atrophy - Gene: SMN1. Autosomal Recessive. Spinal Muscular Atrophy. Variant (1): SMN1 copy number. Detection Rate: Mixed or Other Caucasian 95%.

Spondylothoracic Dysostosis - Gene: MESP2. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_001039958:1-2. Detection Rate: Mixed or Other Caucasian >99%.

Sulfate Transporter-related Osteochondrodysplasia - Gene: SLC26A2. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000112:2-3. Detection Rate: Mixed or Other Caucasian >99%.

TGM1-related Autosomal Recessive Congenital Ichthyosis - Gene: TGM1. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000359:2-15. Detection Rate: Mixed or Other Caucasian >99%.

**TPP1-related Neuronal Ceroid Lipofuscinosis** - Gene: TPP1. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000391:1-13. Detection Rate: Mixed or Other Caucasian >99%.

**Tyrosinemia Type I** - Gene: FAH. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000137:1-14. Detection Rate: Mixed or Other Caucasian >99%.

**Tyrosinemia Type II** - Gene: TAT. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000353:2-12. Detection Rate: Mixed or Other Caucasian >99%.

**USH1C-related Disorders** - Gene: USH1C. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_153676:1-27. Detection Rate: Mixed or Other Caucasian >99%.

**USH2A-related Disorders** - Gene: USH2A. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_206933:2-72. Detection Rate: Mixed or Other Caucasian 94%.

**Usher Syndrome Type 3** - Gene: CLRN1. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_174878:1-3. **Detection Rate**: Mixed or Other Caucasian >99%.

Very Long Chain Acyl-CoA Dehydrogenase Deficiency - Gene: ACADVL. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000018:1-20. Detection Rate: Mixed or Other Caucasian >99%.

Wilson Disease - Gene: ATP7B. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000053:1-21. Detection Rate: Mixed or Other Caucasian >99%.

X-linked Adrenoleukodystrophy - Gene: ABCD1. X-linked Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000033:1-6. Detection Rate: Mixed or Other Caucasian 77%.

X-linked Alport Syndrome - Gene: COL4A5. X-linked Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000495:1-51. Detection Rate: Mixed or Other Caucasian 95%.

X-linked Congenital Adrenal Hypoplasia - Gene: NR0B1. X-linked Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000475:1-2. Detection Rate: Mixed or Other Caucasian 99%.

X-linked Juvenile Retinoschisis - Gene: RS1. X-linked Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000330:1-6. Detection Rate: Mixed or Other Caucasian 98%

X-linked Myotubular Myopathy - Gene: MTM1, X-linked Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000252:2-15. Detection Rate: Mixed or Other Caucasian 98%.

X-linked Severe Combined Immunodeficiency - Gene: IL2RG. X-linked Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000206:1-8. Detection Rate: Mixed or Other Caucasian >99%.

Xeroderma Pigmentosum Group A - Gene: XPA. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_000380:1-6. Detection Rate: Mixed or Other Caucasian >99%.

Xeroderma Pigmentosum Group C - Gene: XPC. Autosomal Recessive. Sequencing with Copy Number Analysis. Exons: NM\_004628:1-16. Detection Rate: Mixed or Other Caucasian 97%.



SEATTLE SPERM BANK

Attn: Dr. Jeffrey Olliffe NPI: 1306838271

Report Date: 04/10/2018

MALE DONOR 123

DONOR 12315 DOB:

Ethnicity: Mixed or Other

Caucasian

Barcode: 11004212276685

FEMALE N/A

# Risk Calculations

Below are the risk calculations for all conditions tested. Since negative results do not completely rule out the possibility of being a carrier, the **residual risk** represents the patient's post-test likelihood of being a carrier and the **reproductive risk** represents the likelihood the patient's future children could inherit each disease. These risks are inherent to all carrier screening tests, may vary by ethnicity, are predicated on a negative family history and are present even after a negative test result. Inaccurate reporting of ethnicity may cause errors in risk calculation. The reproductive risk presented is based on a hypothetical pairing with a partner of the same ethnic group.

†Indicates a positive result. See the full clinical report for interpretation and details.

Disease	DONOR 12315 Residual Risk	Reproductive Risk
11-beta-hydroxylase-deficient Congenital Adrenal Hyperplasia	1 in 3,800	< 1 in 1,000,000
21-hydroxylase-deficient Congenital Adrenal Hyperplasia	1 in 1,400	1 in 310,000
6-pyruvoyl-tetrahydropterin Synthase Deficiency	< 1 in 50,000	< 1 in 1,000,000
ABCC8-related Hyperinsulinism	1 in 11,000	< 1 in 1,000,000
Adenosine Deaminase Deficiency	1 in 22,000	< 1 in 1,000,000
Alpha Thalassemia	Alpha globin status: aa/aa.	Not calculated
Alpha-mannosidosis	1 in 35,000	< 1 in 1,000,000
Alpha-sarcoglycanopathy	1 in 45,000	< 1 in 1,000,000
Alstrom Syndrome	< 1 in 50,000	< 1 in 1,000,000
AMT-related Glycine Encephalopathy	1 in 22,000	< 1 in 1,000,000
Andermann Syndrome	< 1 in 50,000	< 1 in 1,000,000
Argininemia	< 1 in 17,000	< 1 in 1,000,000
Argininosuccinic Aciduria	1 in 13,000	< 1 in 1,000,000
ARSACS	< 1 in 44,000	< 1 in 1,000,000
Aspartylglycosaminuria	< 1 in 50,000	< 1 in 1,000,000
Ataxia with Vitamin E Deficiency	< 1 in 50,000	< 1 in 1,000,000
Ataxia-telangiectasia	1 in 8,200	< 1 in 1,000,000
ATP7A-related Disorders	< 1 in 1,000,000	1 in 600,000
Autosomal Recessive Osteopetrosis Type 1	1 in 35,000	< 1 in 1,000,000
Bardet-Biedl Syndrome, BBS1-related	1 in 16,000	< 1 in 1,000,000
Bardet-Biedl Syndrome, BBS10-related	1 in 16,000	< 1 in 1,000,000
Bardet-Biedl Syndrome, BBS12-related	< 1 in 50,000	< 1 in 1,000,000
Bardet-Biedl Syndrome, BBS2-related	< 1 in 50,000	< 1 in 1,000,000
Beta-sarcoglycanopathy	< 1 in 50,000	< 1 in 1,000,000
Biotinidase Deficiency	1 in 13,000	1 in 650,000
Bloom Syndrome	< 1 in 50,000	< 1 in 1,000,000
Calpainopathy	1 in 13,000	< 1 in 1,000,000
Canavan Disease	< 1 in 31,000	< 1 in 1,000,000
Carbamoylphosphate Synthetase I Deficiency	< 1 in 57,000	< 1 in 1,000,000
Carnitine Palmitoyltransferase IA Deficiency	< 1 in 50,000	< 1 in 1,000,000
Carnitine Palmitoyltransferase II Deficiency	< 1 in 50,000	< 1 in 1,000,000
Cartilage-hair Hypoplasia	< 1 in 50,000	< 1 in 1,000,000
Cerebrotendinous Xanthomatosis	1 in 11,000	< 1 in 1,000,000
Citrullinemia Type 1	1 in 12,000	< 1 in 1,000,000
CLN3-related Neuronal Ceroid Lipofuscinosis	1 in 22,000	< 1 in 1,000,000
CLN5-related Neuronal Ceroid Lipofuscinosis	< 1 in 50,000	< 1 in 1,000,000
CLN6-related Neuronal Ceroid Lipofuscinosis	1 in 43,000	< 1 in 1,000,000
Cohen Syndrome	< 1 in 15,000	< 1 in 1,000,000
COL4A3-related Alport Syndrome	1 in 6,200	< 1 in 1,000,000
COL4A4-related Alport Syndrome	1 in 12,000	< 1 in 1,000,000
Congenital Disorder of Glycosylation Type Ia	1 in 16,000	< 1 in 1,000,000
Congenital Disorder of Glycosylation Type Ib	< 1 in 50,000	< 1 in 1,000,000
Congenital Disorder of Glycosylation Type Ic	< 1 in 50,000	< 1 in 1,000,000
Congenital Finnish Nephrosis	< 1 in 50,000	< 1 in 1,000,000
Costeff Optic Atrophy Syndrome	< 1 in 50,000	< 1 in 1,000,000
Cystic Fibrosis	1 in 2,700	1 in 290,000
Cystinosis	1 in 22,000	< 1 in 1,000,000
D-bifunctional Protein Deficiency	1 in 9,000	< 1 in 1,000,000
	000 000 PERSON	- 1 111 1,000,000



SEATTLE SPERM BANK Attn: Dr. Jeffrey Olliffe NPI: 1306838271

Report Date: 04/10/2018

MALE

FEMALE N/A

DONOR 12315 DOB:

Ethnicity: Mixed or Other

Caucasian

Barcode: 11004212276685

Delta-sarcglyanopathy	D1-20002540	DONOR 12315	Donnadustina
Dystrephinopathy (including Duchenne/Becker Muscular Dystrophy)	Disease		Reproductive Risk
		< 1 in 40,000	< 1 in 1,000,000
RECCF-related Diowiders		1 in 11,000	
SECC-elated Disorders	EPCC6 related Discretes	Not calculated	
EVC-related Ellis-van Creveld Syndrome		1 in 26,000	< 1 in 1,000,000
EVC2-related Ellis-van Creveld Syndrome			< 1 in 1,000,000
Familial Dysautonomia Familial Mediterranean Fever Fancinal Amenia Complementation Group A Familial Mediterranean Fever Fancinal Amenia Complementation Group A Fancinal Amenia Complementation Group A Fancinal Amenia Type C Fancinal Type T Fancinal Amenia Type C Fancinal Type T Fancinal Amenia Type C Fancinal Type T	EVC2-related Ellis-van Creveld Syndrome		< 1 in 1,000,000
Familial Mediterranean Fever			< 1 in 1,000,000
Familal Mediterranean Fever   \$11 in 50,000	18.77 S. G. 18.18 S.		1 in 80,000
Fancoil Anemia Complementation Group A Fancoil Anemia Type C FRRP-related Disorders FRRP-re			< 1 in 1,000,000
FRRP-related Disorders			< 1 in 1,000,000
FKRP-related Disorders	Fanconi Anemia Type C		
F. N. Prélated Disorders			
Salactosimase Deficiency	FKTN-related Disorders		
Camma-sarcoglycanopathy	Galactokinase Deficiency		
Saucher Disease   1 in 2000			< 1 in 1,000,000
GB2-related DFNeth Nonsyndromic Hearing Loss and Deafness	Gamma-sarcoglycanopathy		
Signate   Signature   Signat	Gaucher Disease		
GLDC-related Bisorders GLDC-related Glycine Encephalopathy GLDC-related Glycine Encephalopathy GLDC-related Glycine Encephalopathy GLDC-related Glycine Encephalopathy Glycogen Storage Disease Type Ia Glycogen Storage Disease Type Ib Glycogen Storage Disease Type Ib Glycogen Storage Disease Type III Glycogen Storage Disease Glycogen G	GJB2-related DFNB1 Nonsyndromic Hearing Loss and Deafness		
Silvaric Acidemia Type 1	GLB1-related Disorders		
Glycogen Storage Disease Type la 1 in 10,000	GLDC-related Glycine Encephalopathy		
Signar Storage Disease Type   1	Glutaric Acidemia Type 1		
Silvegen Storage Disease Type   B	Glycogen Storage Disease Type Ia		
Signature   Strage Disease   Type   III	Glycogen Storage Disease Type Ib		
SAPACHE Syndrome	Glycogen Storage Disease Type III		
STACE Syndrome   1 in 15,000			
His Beta Chain-related Hemoglobinopathy (Including Beta Thalassemia and Sickle Cell Disease)			
In 99,000   In 990,000   In 990,000   In 990,000   In 990,000   In 990,000   In 1,000,000   In			
Herelitz   Jructional Epidermolysis Bullosa, LAMA3-related	Sickle Coll Disease)		
Herlitz Junctional Epidermolysis Bullosa, LAMA3-related		1 111 5,000	1 in 990,000
Herlitz   Junctional Epidermolysis Bullosa, LAMBA3-related	Herlitz Junctional Enidormalisis Dulles and a second	1 in 8,000	< 1 in 1,000,000
Herlitz Junctional Epidermolysis Bullosa, LAMC2-related	Herlitz Junctional Epidermolysis Bullosa, LAMA3-related	< 1 in 50,000	
Hescoaminidase A Deficiency (Including Tay-Sachs Disease)	Herlitz Junctional Enidermolysis Bullosa, LAMC3 related		
Holocarboxylase Synthetase Deficiency Holocarboxylase Synthetase Deficiency Homocystinuria Caused by Cystathionine Beta-synthase Deficiency Hypophosphatasia, Autosomal Recessive In 15,000 Inclusion Body Myopathy 2 In 15,000 In 11,000,000 Inclusion Body Myopathy 2 In 15,000 In	Hexosaminidase A Deficiency (Including Tay-Sachs Disease)		< 1 in 1,000,000
Holocarboxylase Synthetase Deficiency	HMG-CoA Lyase Deficiency		< 1 in 1,000,000
Homocystinuria Caused by Cystathionine Beta-synthase Deficiency			< 1 in 1,000,000
Hypophosphatasia, Autosomal Recessive	Homocystinuria Caused by Cystathionine Beta-synthase Deficiency		< 1 in 1,000,000
Hypophosphatasia, Autosomal Recessive	Hydrolethalus Syndrome		< 1 in 1,000,000
Isovaleric Acidemia	Hypophosphatasia, Autosomal Recessive		
1 in 25,000	Inclusion Body Myopathy 2		
String   Syndrome 2			
Krabbe Disease LAMA2-related Muscular Dystrophy Leigh Syndrome, French-Canadian Type Lipoamide Dehydrogenase Deficiency Lipoamide Dehydrogenase Deficiency Lipoid Congenital Adrenal Hyperplasia Lysosomal Acid Lipase Deficiency Lipoid Eyrup Urine Disease Type 1B Maple Syrup Urine Disease Type 1B Maple Syrup Urine Disease Type 1B Lin 1,000,000 Maple Syrup Urine Disease Type II Lin 1,000,000 Medium Chain Acyl-CoA Dehydrogenase Deficiency Lipo3,000 Medium Chain Acyl-CoA Dehydrogenase Deficiency Lipo3,000 Metchromatic Leukoencephalopathy with Subcortical Cysts Metchromatic Leukodystrophy Methylmalonic Acidemia, cblA Type Lin 1,000,000 Methylmalonic Acidemia, cblB Type Lin 1,000,000 MKS1-related Disorders Mucolipidosis IV Lin 1,000,000 Lin 1,000,000 Lipo3,000 Lip			
LAMA2-related Muscular Dystrophy	KCNJ11-related Familial Hyperinsulinism		
Leigh Syndrome, French-Canadian Type Lipoamide Dehydrogenase Deficiency Lipoamide Dehydrogenase Deficiency Lipoid Congenital Adrenal Hyperplasia Lysosomal Acid Lipase Deficiency Maple Syrup Urine Disease Type 1B Maple Syrup Urine Disease Type 1B Maple Syrup Urine Disease Type Ia Maple Syrup Urine Disease Type Ia Maple Syrup Urine Disease Type II  Medium Chain Acyl-CoA Dehydrogenase Deficiency Medium Chain Acyl-CoA Dehydrogenase Deficiency Megalencephalic Leukoencephalopathy with Subcortical Cysts Metachromatic Leukodystrophy Methylmalonic Acidemia, cblA Type Methylmalonic Acidemia, cblB Type Methylmalonic Acidemia, cblB Type Methylmalonic Acidemia, cblB Type Methylmalonic Acidemia and Homocystinuria, cblC Type Mucolipidosis III Gamma Mucolipidosis IV  1 in 50,000 1 in 1,000,000	Krabbe Disease		
Lipoamide Dehydrogenase Deficiency Lipoid Congenital Adrenal Hyperplasia Lysosomal Acid Lipase Deficiency Maple Syrup Urine Disease Type 1B Maple Syrup Urine Disease Type 1B Maple Syrup Urine Disease Type 1a Maple Syrup Urine Disease Type Ia Maple Syrup Urine Disease Type II Medium Chain Acyl-CoA Dehydrogenase Deficiency Megalencephalic Leukoencephalopathy with Subcortical Cysts Metachromatic Leukodystrophy Metachromatic Leukodystrophy Methylmalonic Acidemia, cblA Type Methylmalonic Acidemia, cblB Type Methylmalonic Acidemia, cblB Type Methylmalonic Acidemia, cblB Type Methylmalonic Acidemia, cblB Type Methylmalonic Acidemia Mucolipidosis III Gamma Mucolipidosis IV  1 in 50,000  1 in 1,000,000  1 in 10,000,000	LAMA2-related Muscular Dystrophy		
Lipoamide Dehydrogenase Deficiency       <1 in 50,000       <1 in 1,000,000         Lipoid Congenital Adrenal Hyperplasia       <1 in 50,000       <1 in 1,000,000         Lysosomal Acid Lipase Deficiency       1 in 18,000       <1 in 1,000,000         Maple Syrup Urine Disease Type 1B       1 in 25,000       <1 in 1,000,000         Maple Syrup Urine Disease Type II       1 in 42,000       <1 in 1,000,000         Medium Chain Acyl-CoA Dehydrogenase Deficiency       1 in 5,900       <1 in 1,000,000         Megalencephalic Leukoencephalopathy with Subcortical Cysts       <1 in 50,000       <1 in 1,000,000         Metachromatic Leukodystrophy       1 in 20,000       <1 in 1,000,000         Methylmalonic Acidemia, cblA Type       <1 in 50,000       <1 in 1,000,000         Methylmalonic Acidemia, cblB Type       1 in 48,000       <1 in 1,000,000         MKS1-related Disorders       <1 in 50,000       <1 in 1,000,000         Mucolipidosis III Gamma       <1 in 50,000       <1 in 1,000,000         Mucolipidosis IV       <1 in 50,000       <1 in 1,000,000	Leigh Syndrome, French-Canadian Type		
Lysosomal Acid Lipase Deficiency	Lipoamide Dehydrogenase Deficiency		
Maple Syrup Urine Disease Type 1B       1 in 18,000       < 1 in 1,000,000         Maple Syrup Urine Disease Type Ia       1 in 25,000       < 1 in 1,000,000         Maple Syrup Urine Disease Type II       1 in 42,000       < 1 in 1,000,000         Medium Chain Acyl-CoA Dehydrogenase Deficiency       1 in 5,900       < 1 in 1,000,000         Megalencephalic Leukoencephalopathy with Subcortical Cysts       < 1 in 5,900       < 1 in 1,000,000         Metachromatic Leukodystrophy       1 in 20,000       < 1 in 1,000,000         Methylmalonic Acidemia, cblA Type       < 1 in 50,000       < 1 in 1,000,000         Methylmalonic Acidemia, cblB Type       1 in 48,000       < 1 in 1,000,000         MKS1-related Disorders       < 1 in 50,000       < 1 in 1,000,000         Mucolipidosis III Gamma       < 1 in 50,000       < 1 in 1,000,000         Mucolipidosis IV       < 1 in 50,000       < 1 in 1,000,000	Lipoid Congenital Adrenal Hyperplasia	< 1 in 50,000	
Maple Syrup Urine Disease Type IB       1 in 25,000       < 1 in 1,000,000         Maple Syrup Urine Disease Type II       1 in 42,000       < 1 in 1,000,000         Medium Chain Acyl-CoA Dehydrogenase Deficiency       1 in 5,900       < 1 in 1,000,000         Megalencephalic Leukoencephalopathy with Subcortical Cysts       < 1 in 50,000       < 1 in 1,000,000         Metachromatic Leukodystrophy       1 in 20,000       < 1 in 1,000,000         Methylmalonic Acidemia, cblA Type       < 1 in 50,000       < 1 in 1,000,000         Methylmalonic Acidemia, cblB Type       1 in 48,000       < 1 in 1,000,000         MKS1-related Disorders       < 1 in 50,000       < 1 in 1,000,000         Mucolipidosis III Gamma       < 1 in 50,000       < 1 in 1,000,000         Mucolipidosis IV       < 1 in 50,000       < 1 in 1,000,000	Mania Surum Union Di	1 in 18,000	
Maple Syrup Urine Disease Type II       1 in 42,000       < 1 in 1,000,000         Medium Chain Acyl-CoA Dehydrogenase Deficiency       1 in 13,000       < 1 in 1,000,000         Megalencephalic Leukoencephalopathy with Subcortical Cysts       < 1 in 5,900       < 1 in 1,000,000         Metachromatic Leukodystrophy       1 in 20,000       < 1 in 1,000,000         Methylmalonic Acidemia, cblA Type       < 1 in 50,000       < 1 in 1,000,000         Methylmalonic Acidemia, cblB Type       1 in 48,000       < 1 in 1,000,000         MKS1-related Disorders       < 1 in 50,000       < 1 in 1,000,000         Mucolipidosis III Gamma       < 1 in 50,000       < 1 in 1,000,000         Mucolipidosis IV       < 1 in 50,000       < 1 in 1,000,000	Maple Syrup Urine Disease Type 1B	1 in 25,000	
Medium Chain Acyl-CoA Dehydrogenase Deficiency   1 in 13,000   1 in 5,900   1 in 1,000,000	Maple Syrup Urine Disease Type Ia	1 in 42,000	
Megalencephalic Leukoencephalopathy with Subcortical Cysts       < 1 in 50,000       < 1 in 1,000,000         Metachromatic Leukodystrophy       1 in 20,000       < 1 in 1,000,000         Methylmalonic Acidemia, cblA Type       < 1 in 50,000       < 1 in 1,000,000         Methylmalonic Acidemia, cblB Type       1 in 48,000       < 1 in 1,000,000         Methylmalonic Aciduria and Homocystinuria, cblC Type       1 in 16,000       < 1 in 1,000,000         MKS1-related Disorders       < 1 in 50,000       < 1 in 1,000,000         Mucolipidosis III Gamma       < 1 in 50,000       < 1 in 1,000,000         Mucolipidosis IV       < 1 in 50,000       < 1 in 1,000,000	Medium Chain Acyl-Coa Dobydrogonaca Doffel	1 in 13,000	
Metachromatic Leukodystrophy   1 in 20,000   1 in 20,000   1 in 20,000   1 in 1,000,000	Megalencephalic Leukoencephalonathy with subanatical su		
Methylmalonic Acidemia, cblA Type       < 1 in 1,000,000         Methylmalonic Acidemia, cblB Type       < 1 in 50,000         Methylmalonic Aciduria and Homocystinuria, cblC Type       1 in 16,000         MKS1-related Disorders       < 1 in 50,000         Mucolipidosis III Gamma       < 1 in 50,000         Mucolipidosis IV       < 1 in 50,000	Metachromatic Leukodystrophy		
Methylmalonic Acidemia, cblB Type       1 in 48,000       < 1 in 1,000,000         Methylmalonic Aciduria and Homocystinuria, cblC Type       1 in 16,000       < 1 in 1,000,000         MKS1-related Disorders       < 1 in 50,000       < 1 in 1,000,000         Mucolipidosis III Gamma       < 1 in 50,000       < 1 in 1,000,000         Mucolipidosis IV       < 1 in 50,000       < 1 in 1,000,000	Methylmalonic Acidemia, chlA Tyne		< 1 in 1,000,000
Methylmalonic Aciduria and Homocystinuria, cblC Type       1 in 16,000       < 1 in 1,000,000         MKS1-related Disorders       < 1 in 50,000       < 1 in 1,000,000         Mucolipidosis III Gamma       < 1 in 50,000       < 1 in 1,000,000         Mucolipidosis IV       < 1 in 50,000       < 1 in 1,000,000	Methylmalonic Acidemia, cblB Type		< 1 in 1,000,000
MKS1-related Disorders       < 1 in 50,000       < 1 in 1,000,000         Mucolipidosis III Gamma       < 1 in 50,000       < 1 in 1,000,000         Mucolipidosis IV       < 1 in 50,000       < 1 in 1,000,000	Methylmalonic Aciduria and Homocystinuria, chic Type		< 1 in 1,000,000
Mucolipidosis III Gamma < 1 in 50,000 < 1 in 1,000,000 Mucolipidosis IV < 1 in 50,000 < 1 in 1,000,000	MKS1-related Disorders		< 1 in 1,000,000
Mucolipidosis IV < 1 in 50,000 < 1 in 1,000,000			
< 1 in 1,000,000	Mucolipidosis IV		
		50,000	< 1 in 1,000,000



SEATTLE SPERM BANK

Attn: Dr. Jeffrey Olliffe NPI: 1306838271

Report Date: 04/10/2018

MALE

**DONOR 12315** 

DOB: Ethnicity: Mixed or Other

Caucasian

Barcode: 11004212276685

FEMALE N/A

Mucopolysaccharidosis Type II	Disease	DONOR 12315 Residual Risk	Reproductive Risk
Mucopphysicannidasi Type IIIA	Mucopolysaccharidosis Type I		
Mucophysaccharidosis Type IIIB	Mucopolysaccharidosis Type II		
Muscle-ey-brian Disease Muscle-ey-brian Disease Muscle-ey-brian Disease Murcl-related Methymalonic Addemia MUTA-related Methymalonic Addemia MUTA-related Disorders 1 1 100,000 MUTA-related Methymalonic Addemia 1 1 1 100,000 NEB-related Nemaline Myopathy 1 1 1 100,000 NEB-related Nemaline Myopathy 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Mucopolysaccharidosis Type IIIA		
MUT-related Methylmalonic Addemia MUT-related Biorders MUT-related Biorders MUT-related Disorders MUT-related Autosomal Recessive Congenical Lethyous Muthers MUT-related Disorders MUT-related Autosomal Recessive Polycytic Kidney Disease MUT-related Disorders MUT-r	Mucopolysaccharidosis Type IIIB	1 in 25,000	
MUTC-related Methymialonic Addemia MVOTA-related Nemaline Myopathy NEB-related Nemaline Myopathy 11 in 5,000 NEB-related Nemaline Myopathy 11 in 5,000 NEB-rolated Nemaline Myopathy 11 in 5,000 Nemann-Pick Disease Type C Nemann-Pick Disease Type C Nemann-Pick Disease Type C Nemann-Pick Disease Type C Nemann-Pick Disease Sype Sype Sype Sype Sype Sype Sype Syp	Mucopolysaccharidosis Type IIIC	1 in 37,000	
NEP-clated Ploarders		< 1 in 12,000	
NePretack Nemaline Myopathy		1 in 26,000	
Neman-Pick Disease Type C		1 in 15,000	
Nimman-Pick Disease Type C	Nephretic Syndrome Myopathy	< 1 in 6,700	
Niemann-Pick Disease, Type C2	Niemann Bisk Disease Trans	1 in 35,000	
Nimean-Pick Disease, SMPD1-associated   1 in 25,000   1 in 1,000,000	Niemann Bisk Disease Type C	1 in 19,000	
Nimegen Breakage Syndrome	Niemann Bick Disease Type C2	< 1 in 50,000	
Northern Epilepsy	Niimegen Broakage Syndrome	1 in 25,000	
PCCA-related Propinic Acidemia	Northern Enilance	1 in 16,000	
PCCB-related Propionic Acidemia PCDH-IS-related Disorders 1 in 22,000 Propionic PCDH-IS-related Disorder Type 3 1 in 3,300 Peroxisome Biogenesis Disorder Type 4 1 in 9,300 Peroxisome Biogenesis Disorder Type 5 1 in 1,000,000 Peroxisome Biogenesis Disorder Type 6 PEXI-related Cellweger Syndrome Spectrum 1 in 11,000 Peroxisome Biogenesis Disorder Type 6 PEXI-related Autosomal Recessive Polystic Kidney Disease PEXI-related Autosomal Recessive Polystic Kidney Disease 1 in 6,100 Phenylalanine Hydroxylase Deficiency Phenylalanine Hydroxylase Deficiency Polyglandular Autoimmune Syndrome Type 1 1 in 14,000 Primary Hyperoxaluria Type 1 1 in 35,000 1 in 1,000,000 Primary Hyperoxaluria Type 2 1 in 35,000 1 in 1,000,000 Primary Hyperoxaluria Type 2 1 in 35,000 1 in 1,000,000 Primary Hyperoxaluria Type 3 Primary Hyperoxaluria Type 4 Primary Hyperoxaluria Type 3 Primary Hyperoxaluria Type 5 Primary Hyperoxaluria Type 6 Primary Hyperoxaluria Type 7 Primary Hyperoxaluria Type 7 Primary Hyperoxaluria Type 8 Primary Hyperoxaluria Type 9 Primary Hyperoxaluria Type 9 Primary Hyperoxaluria Type 1 Primary Hyperoxaluria Type		< 1 in 50,000	
PCCHIS-related Disorders   1 in 2,2000   1 in 1,000,000   PCCHIS-related Disorder S   1 in 2,2000   1 in 1,000,000   Pendred Syndrome   1 in 7,000   1 in 1,000,000   Pendred Syndrome   1 in 7,000   1 in 1,000,000   Peroxisome Biogenesis Disorder Type 3   1 in 4,000   1 in 1,000,000   Peroxisome Biogenesis Disorder Type 5   1 in 71,000   1 in 1,000,000   Peroxisome Biogenesis Disorder Type 5   1 in 71,000   1 in 1,000,000   Peroxisome Biogenesis Disorder Type 5   1 in 71,000   1 in 1,000,000   PEXI-related Zellwager Syndrome Spectrum   1 in 1,000   1 in 1,000,000   PEXI-related Zellwager Syndrome Spectrum   1 in 1,000   1 in 990,000   PEXI-related Autosomal Recessive Polycystic Kidney Disease   1 in 5,000   1 in 990,000   PHOF1-related Autosomal Recessive Polycystic Kidney Disease   1 in 6,100   1 in 990,000   Phyllandra Autoimmune Syndrome Type 1   1 in 1,400   1 in 1,000,000   Phyllandra Autoimmune Syndrome Type 1   1 in 6,300   1 in 1,000,000   Phyllandra Autoimmune Syndrome Type 1   1 in 6,300   1 in 1,000,000   Phyllandra Autoimmune Syndrome Type 1   1 in 5,000   1 in 1,000,000   Phyllandra Proxyllaria Type 2   1 in 85,000   1 in 1,000,000   Primary Hyperoxaluria Type 2   1 in 85,000   1 in 1,000,000   Primary Hyperoxaluria Type 3   1 in 5,000   1 in 1,000,000   Primary Hyperoxaluria Type 3   1 in 5,000   1 in 1,000,000   Primary Hyperoxaluria Type 3   1 in 1,000,000   1 in 1,000,000   Primary Hyperoxaluria Type 3   1 in 1,000,000   1 in 1,000,000   Primary Hyperoxaluria Type 3   1 in 1,000,000   1 in 1,000,000   Primary Hyperoxaluria Type 3   1 in 1,000,000   1 in 1,000,000   Primary Hyperoxaluria Type 3   1 in 1,000,000   1 in 1,000,000   Primary Hyperoxaluria Type 3   1 in 1,000,000   1 in 1,000,000   Primary Hyperoxaluria Type 3   1 in 1,000,000   1 in 1,000,000   Primary Hyperoxaluria Type 3   1 in 1,000,000   1 in 1,000,000   Primary Hyperoxaluria Type 3   1 in 1,000,000   1 in 1,000,000   Primary Hyperoxaluria Type 3   1 in 1,000,000   1 in 1,000,000   Primary Hyperoxaluria Type 4   1 in 1,000,000	PCCA-related Propionic Acid-mile	< 1 in 1,000,000	
PCDH15-related Disorders	PCCB-related Propionic Acidemia	1 in 4,200	
Pendred Syndrome	PCDH15 related Propionic Acidemia	1 in 22,000	
Peroxisome Biogenesis Disorder Type 4		1 in 5,300	
Peroxisome Biogenesis Disorder Type 4		1 in 7,000	
Peroxisome Biogenesis Disorder Type 5	Peroxisome Biogenesis Disorder Type 3	1 in 44,000	
PEXT-related Zell/geers yndrome Spectrum	Perovisome Biogenesis Disorder Type 4	1 in 9,300	
PEXT-related Zellweger Syndrome Spectrum	Peroxisome Biogenesis Disorder Type 5	< 1 in 71,000	
Phenylalanine Hydroxylase Deficiency	PEXI-related Zellysees Cond.	< 1 in 50,000	
PKHD1-related Autosomal Recessive Polycystic Kidney Disease   1 in 6,100	Phenylalanina Hydroxylasa D. S.	1 in 11,000	
Polyglandular Autoimmune Syndrome Type 1	PKHD1-related Autocomol B	1 in 5,000	
Penne Disease	Polyglandular Autoimmun S. C. J. C.	1 in 6,100	
PPT1-related Neuronal Ceroid Lipofuscinosis	Pompe Disease	1 in 14,000	
Primary Carnitine Deficiency         <1 in 1,000,000           Primary Hyperoxaluria Type 1         1 in 35,000         <1 in 1,000,000           Primary Hyperoxaluria Type 2         1 in 35,000         <1 in 1,000,000           Primary Hyperoxaluria Type 3         1 in 13,000         <1 in 1,000,000           PROPT-Telated Combined Pituitary Hormone Deficiency         1 in 13,000         <1 in 1,000,000           Pycrodysostosis         5 in 50,000         <1 in 1,000,000           Pyruvate Carboxylase Deficiency         1 in 25,000         <1 in 1,000,000           Rizomelic Chondrodysplasia Punctata Type 1         1 in 16,000         <1 in 1,000,000           RTEL1-related Disorders         1 in 16,000         <1 in 1,000,000           Salla Disease         1 in 32,000         <1 in 1,000,000           Salla Disease         1 in 32,000         <1 in 1,000,000           Segawa Syndrome         1 in 50,000         <1 in 1,000,000           Short Chain Acyl-CoA Dehydrogenase Deficiency         1 in 16,000         <1 in 1,000,000           Sjogren-Larsson Syndrome         1 in 9,000         <1 in 1,000,000           Smith-Lemil-Opitz Syndrome         1 in 9,000         <1 in 1,000,000           Spastic Paraplegia Type 15         1 in 7,000         <1 in 1,000,000           Spondylothoracic Dysostosis		1 in 6,300	
Primary Hyperoxaluria Type 1	Primary Carnitine Deficiency	< 1 in 50,000	
Primary Hyperoxaluria Type 2         <1 in 50,000         <1 in 1,000,000           Primary Hyperoxaluria Type 3         1 in 50,000         <1 in 1,000,000           PROP1-related Combined Pituitary Hormone Deficiency         1 in 13,000         <1 in 1,000,000           Pycnuate Carboxylase Deficiency         1 in 150,000         <1 in 1,000,000           Pyruvate Carboxylase Deficiency         1 in 25,000         <1 in 1,000,000           RTEL1-related Disorders         1 in 16,000         <1 in 1,000,000           Salla Disease         <1 in 50,000         <1 in 1,000,000           Sandhoff Disease         1 in 32,000         <1 in 1,000,000           Segawa Syndrome         1 in 32,000         <1 in 1,000,000           Short Chain Acyl-CoA Dehydrogenase Deficiency         1 in 16,000         <1 in 1,000,000           Sjogren-Larsson Syndrome         1 in 9,100         <1 in 1,000,000           Smith-Lemil-Opitz Syndrome         1 in 9,100         <1 in 1,000,000           Spastic Faraplegia Type 15         <1 in 50,000         <1 in 1,000,000           Spinal Muscular Atrophy         Negative for g.271347-G SNP           Spinal Muscular Atrophy         Negative for g.271347-G SNP           Spinal Muscular Atrophy         1 in 1,000,000           Spondylothoracic Dysostosis         1 in 7,70      <	Primary Hyperoxaluria Type 1	< 1 in 50,000	
Primary Hyperoxaluria Type 3		1 in 35,000	
PROP1-related Combined Pituitary Hormone Deficiency	Primary Hyperoxaluria Type 2	< 1 in 50,000	
Pyrrodysostosis	PROP1-related Combined Pituitary Harmon D. F.	1 in 13,000	
Pyruvate Carboxylase Deficiency	Pycnodysostosis		
Ritzomelic Chondrodysplasia Punctata Type 1		< 1 in 50,000	
RTEL1-related Disorders	Rhizomelic Chondrodysplasia Punctata Type 1		
Salla Disease         <1 in 30,000         <1 in 1,000,000           Sandhoff Disease         <1 in 30,000         <1 in 1,000,000           Segawa Syndrome         1 in 32,000         <1 in 1,000,000           Short Chain Acyl-CoA Dehydrogenase Deficiency         1 in 16,000         <1 in 1,000,000           Sjogren-Larsson Syndrome         1 in 19,000         <1 in 1,000,000           Smith-Lemli-Opitz Syndrome         1 in 4,900         1 in 970,000           Spastic Paraplegia Type 15         <1 in 50,000         <1 in 1,000,000           Spinal Muscular Atrophy         Negative for g.27134T>G SNP           Spinal Muscular Atrophy         SMN1:2 copies         1 in 110,000           Spondylothoracic Dysostosis         1 in 770         1 in 1,000,000           Sulfate Transporter-related Osteochondrodysplasia         1 in 1,000         1 in 1,000,000           TGM1-related Autosomal Recessive Congenital Ichthyosis         1 in 2,000         1 in 1,000,000           TPP1-related Neuronal Ceroid Lipofuscinosis         1 in 30,000         1 in 1,000,000           Tyrosinemia Type I         1 in 17,000         1 in 1,000,000           Tyrosinemia Type II         1 in 2,000         1 in 1,000,000           USH2A-related Disorders         1 in 2,200         1 in 1,000,000           USH2A-related Disorders	RTEL1-related Disorders		
Segawa Syndrome			< 1 in 1,000,000
Short Chain Acyl-CoA Dehydrogenase Deficiency	Sandhoff Disease		< 1 in 1,000,000
Short Chain Acyl-CoA Dehydrogenase Deficiency   1 in 1,000,000   1 in 1,	Segawa Syndrome		< 1 in 1,000,000
Signer-Larsson Syndrome			< 1 in 1,000,000
Smith-Lemli-Opitz Syndrome       1 in 4,000       <1 in 1,000,000         Spastic Paraplegia Type 15       1 in 50,000       <1 in 970,000         Spinal Muscular Atrophy       Negative for g.27134T>G SNP         Smith-Lemli Muscular Atrophy       SMN1: 2 copies       1 in 110,000         Spondylothoracic Dysostosis       1 in 770         Sulfate Transporter-related Osteochondrodysplasia       1 in 50,000       <1 in 1,000,000         TGM1-related Autosomal Recessive Congenital Ichthyosis       1 in 22,000       <1 in 1,000,000         TPP1-related Neuronal Ceroid Lipofuscinosis       1 in 30,000       <1 in 1,000,000         Tyrosinemia Type I       1 in 17,000       <1 in 1,000,000         Tyrosinemia Type II       1 in 17,000       <1 in 1,000,000         USH1C-related Disorders       1 in 25,000       <1 in 1,000,000         USH2A-related Disorders       1 in 35,000       <1 in 1,000,000         USH2A-related Disorders       1 in 2,200       <1 in 1,000,000         Usher Syndrome Type 3       <1 in 50,000       <1 in 1,000,000         Very Long Chain Acyl-CoA Dehydrogenase Deficiency       1 in 8,800       <1 in 1,000,000         Wilson Disease       1 in 8,600       <1 in 1,000,000         X-linked Adrenoleukodystrophy       1 in 90,000       <1 in 1,000,000	Sjogren-Larsson Syndrome		< 1 in 1,000,000
Spastic Paraplegia Type 15         1 in 970,000           Spinal Muscular Atrophy         Negative for g.27134T>G SNP           Spondylothoracic Dysostosis         1 in 770           Sulfate Transporter-related Osteochondrodysplasia         1 in 50,000           TGM1-related Autosomal Recessive Congenital Ichthyosis         1 in 22,000           TPP1-related Neuronal Ceroid Lipofuscinosis         1 in 30,000           Tyrosinemia Type I         1 in 17,000           Tyrosinemia Type II         1 in 25,000           USH1C-related Disorders         1 in 35,000           USH2A-related Disorders         1 in 35,000           Usher Syndrome Type 3         1 in 2,200           Very Long Chain Acyl-CoA Dehydrogenase Deficiency         1 in 8,800           Wilson Disease         1 in 8,600           X-linked Adrenoleukodystrophy         1 in 90,000           X-linked Alport Syndrome         1 in 42,000	Smith-Lemli-Opitz Syndrome		< 1 in 1,000,000
Spinal Muscular Atrophy   Negative for g.27134T>G SNP   SMN1: 2 copies   1 in 1,000,000	Spastic Paraplegia Type 15		1 in 970,000
SMN1: 2 copies			< 1 in 1,000,000
Spondylothoracic Dysostosis	Spinal Muscular Atrophy		
Spondylothoracic Dysostosis       < 1 in 50,000       < 1 in 1,000,000         Sulfate Transporter-related Osteochondrodysplasia       1 in 11,000       < 1 in 1,000,000         TGM1-related Autosomal Recessive Congenital Ichthyosis       1 in 22,000       < 1 in 1,000,000         TPP1-related Neuronal Ceroid Lipofuscinosis       1 in 30,000       < 1 in 1,000,000         Tyrosinemia Type I       1 in 17,000       < 1 in 1,000,000         Tyrosinemia Type II       1 in 25,000       < 1 in 1,000,000         USH1C-related Disorders       1 in 35,000       < 1 in 1,000,000         USH2A-related Disorders       1 in 35,000       < 1 in 1,000,000         Usher Syndrome Type 3       1 in 2,200       < 1 in 1,000,000         Very Long Chain Acyl-CoA Dehydrogenase Deficiency       1 in 50,000       < 1 in 1,000,000         Wilson Disease       1 in 8,800       < 1 in 1,000,000         X-linked Adrenoleukodystrophy       1 in 90,000       < 1 in 1,000,000         X-linked Alport Syndrome       1 in 42,000	2. 158	the state of the s	1 in 110,000
Tight	Spondylothoracic Dysostosis		
### TGM1-related Autosomal Recessive Congenital Ichthyosis ### Tim 1,000,000 ### TPP1-related Neuronal Ceroid Lipofuscinosis ### Tim 1,000,000 ### Tyrosinemia Type I ### Tyrosinemia Type II ### Tim 17,000 ### USH1C-related Disorders ### USH2A-related Disorders ### USH2A-related Disorders ### Usher Syndrome Type 3 ### Usher Syndrome Type 3 ### Very Long Chain Acyl-CoA Dehydrogenase Deficiency ### Usher Syndrome Type 3 ### Very Long Chain Acyl-CoA Dehydrogenase Deficiency ### Usher Syndrome Type 3 ### Usher S	Sulfate Transporter-related Osteochondrodysplasia		
TPP1-related Neuronal Ceroid Lipofuscinosis	TGM1-related Autosomal Recessive Congenital Ichthyosis		
Tyrosinemia Type I  Tyrosinemia Type II  USH1C-related Disorders  USH2A-related Disorders  Usher Syndrome Type 3  Very Long Chain Acyl-CoA Dehydrogenase Deficiency Wilson Disease X-linked Adrenoleukodystrophy X-linked Alport Syndrome  Not callwared  1 in 17,000  1 in 17,000  1 in 25,000  1 in 35,000  1 in 2,200  1 in 2,200  1 in 50,000  1 in 8,800  1 in 1,000,000  1 in 8,800  1 in 8,600  1 in 1,000,000	TPP1-related Neuronal Ceroid Lipofuscinosis		< 1 in 1,000,000
USH1C-related Disorders	Tyrosinemia Type I		
USH2A-related Disorders  USH2A-related Disorders  1 in 35,000  1 in 2,200  41 in 1,000,000  41 in 1,000,000  41 in 1,000,000  41 in 50,000  41 in 50,000  41 in 1,000,000  41 in	Tyrosinemia Type II		
Usher Syndrome Type 3  Very Long Chain Acyl-CoA Dehydrogenase Deficiency Wilson Disease X-linked Adrenoleukodystrophy X-linked Alport Syndrome  1 in 2,200  < 1 in 50,000  < 1 in 50,000  < 1 in 8,800  < 1 in 1,000,000   1 in 90,000  X-linked Alport Syndrome  Not calculated			
Very Long Chain Acyl-CoA Dehydrogenase Deficiency       1 in 50,000       < 1 in 1,000,000         Wilson Disease       1 in 8,800       < 1 in 1,000,000         X-linked Adrenoleukodystrophy       1 in 8,600       < 1 in 1,000,000         X-linked Alport Syndrome       1 in 90,000       1 in 42,000			
Wilson Disease       1 in 8,800       < 1 in 1,000,000         X-linked Adrenoleukodystrophy       1 in 8,600       < 1 in 1,000,000         X-linked Alport Syndrome       1 in 90,000       1 in 42,000	Usher Syndrome Type 3		
Wilson Disease       < 1 in 1,000,000         X-linked Adrenoleukodystrophy       1 in 90,000         X-linked Alport Syndrome       1 in 90,000         1 in 42,000	Very Long Chain Acyl-CoA Dehydrogenase Deficiency		
X-linked Adrenoleukodystrophy 1 in 90,000 1 in 42,000	Wilson Disease		
A-linked Alport Syndrome	X-linked Adrenoleukodystrophy		
Not calculated	X-linked Alport Syndrome		
		. Tot concolaced	Not calculated



SEATTLE SPERM BANK

Attn: Dr. Jeffrey Olliffe NPI: 1306838271

Report Date: 04/10/2018

DONOR 12315

MALE

DOB:

Ethnicity: Mixed or Other

Caucasian

Barcode: 11004212276685

FEMALE N/A

Disease

X-linked Congenital Adrenal Hypoplasia X-linked Juvenile Retinoschisis X-linked Myotubular Myopathy X-linked Severe Combined Immunodeficiency Xeroderma Pigmentosum Group A Xeroderma Pigmentosum Group C

DONOR 12315 Residual Risk

< 1 in 1,000,000 < 1 in 1,000,000 Not calculated < 1 in 1,000,000 < 1 in 50,000 1 in 7,300

Reproductive Risk

< 1 in 1,000,000 1 in 50,000 Not calculated 1 in 200,000 < 1 in 1,000,000 < 1 in 1,000,000